AKRO News and Press, Akero Therapeutics Inc. From 05/18/21

AKRO has produced highly competitive phase 2a data and has a phase 2b running with data later this year. NASH is a vast market and AKRO looks like the real deal in the space. The company is adequately financed for the next 18 months at the least. For further details see: ...

SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today reported first quarter financial results for the p...

SOUTH SAN FRANCISCO, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced the appointment of Yuan Xu, Ph.D....

89bio ([[ETNB]] +6.9%) has surged today after Cantor Fitzgerald initiated coverage on the stock with an overweight rating and the price target at $58.00 per share implies as much as ~124.7% premium to the previous close.89bio’s lone asset BIO89-100 is set to undergo a Phase 2b tri...

SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced the first patient has been randomized for dosing...

-- 33% of patients treated with efruxifermin (EFX) (4 of 12) improved by one fibrosis stage without worsening of NASH -- -- 25% of EFX patients (3 of 12) showed NASH resolution -- -- Rapid fibrosis improvement in cirrhotic patients after only 16 weeks of EFX treatment, t...

SOUTH SAN FRANCISCO, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that the company plans to discuss new efficacy a...

Akero Therapeutics (AKRO): Q4 GAAP EPS of -$0.86 misses by $0.29.Cash, cash equivalents and short-term marketable securities of $268.4M for the year ended December 31, 2020Press Release For further details see: Akero Therapeutics EPS misses by $0.29

SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today reported fourth quarter and full year financial ...

Akero Therapeutics to Participate in Upcoming Virtual Healthcare Conferences in March PR Newswire SAN FRANCISCO , Feb. 23, 2021 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformat...